Akums Drugs & Pharmaceuticals Ltd Q1 FY27 Results Analysis: CDMO Margin Outperforms, PAT Surges

Akums Drugs & Pharmaceuticals Ltd's Q1 FY27 numbers came in strong, with revenue of Rs. 1,166.63 Cr (+13.92% YoY) and PAT growth of +57.55% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quarter Snapshot

CDMO margin outperformance and strong PAT growth drive positive quarter. Concerns around domestic branded margin compression and API losses need monitoring, but overall execution quality is good.

Key Investment Insights

Key Positives

• Consolidated revenue grew 13.92% YoY to Rs.1,166.63 Cr, CDMO segment grew 18.55% YoY to Rs.964.21 Cr
• Consolidated PAT (owners) surged 57.55% YoY to Rs.100.01 Cr, EPS rose 57.35% to Rs.6.53
• EBITDA margin expanded 238 bps YoY to 14.97%, highest in at least five quarters
• CDMO segment before-depreciation margin reached 16.95%, well above the guided 13-14% range
• Trade Generics remained EBITDA-positive for the second consecutive quarter, sustaining turnaround
• Subsidiary contribution to PAT tripled from Rs.18.61 Cr to Rs.55.17 Cr YoY
• Effective tax rate at 27.48% came in below the guided ~29%, providing a natural tailwind

Risk Factors

• Domestic Branded Formulations margin compressed 449 bps YoY to 10.26%, the most significant segment-level negative surprise
• API segment revenue declined 29.71% YoY and remained loss-making at -Rs.3.90 Cr before-depreciation
• CDMO revenue growth decelerated from >25% in Q3/Q4 FY26 to 18.55% in Q1FY27
• Trade Generics revenue declined 9.47% YoY, though margin turned positive
• Contingent liability from IT assessment orders of Rs.156 Cr is under appeal, with Rs.4.70 Cr deposited under protest